Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.
Reddy VY, Gerstenfeld EP, Mountantonakis SE, Patel C, Ellenbogen KA, Harding JD, Gibson DN, Natale A, Waks JW, Calkins H, Gupta SK, Woods CE, Whang W, Daccarett M, Cuoco FA, Delurgio DB, Richards E, Martens MD, Sutton B, Mansour M, ADVENT-LTO Study Investigators
- DOI
- 10.1038/s41591-026-04246-4
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/11887c4d-28ff-4cdb-8b9b-9268f471a10f is authoritative.
How this rating was calculated
- IntegrityIntegrity concern−0.5★
- ClaimsOverstated claim−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingStudy design partially met−0.25★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy endpoint is freedom from atrial tachyarrhythmia recurrence (AF/AT/AFL lasting ≥30 seconds), cardioversion, or repeat ablation. This is a surrogate for clinical outcomes such as stroke or mortality. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD) nor cite validated evidence linking this surrogate to hard clinical outcomes. The claim of 'preserved effectiveness' and 'support widespread adoption' is based on this surrogate.
“For the primary endpoint of 4-year treatment success, PFA demonstrated preserved effectiveness compared to thermal ablation (72.8% PFA, 64.3% thermal; P = 0.12).”
- 02Treatment effect not shown to be clinically meaningful
The primary effect size is a 72.8% vs 64.3% success rate, which is not statistically significant (P=0.12). The difference of 8.5 percentage points is not anchored to a minimal clinically important difference or biological meaningfulness. The paper reports trends and non-significant differences, and the only significant finding (fewer repeat ablations) is a secondary endpoint. The effect size is not presented as clinically material.
“the estimated probabilities of 4-year treatment success were 72.8% for PFA and 64.3% for thermal ablation (log-rank P = 0.12)”
- 03Conclusion reaches beyond the evidence
These long-term data support widespread adoption of PFA for the treatment of AF.
“Coupled with the safety advantages of PFA over thermal ablation, these long-term data support widespread adoption of PFA for the treatment of AF.”
AbstractFind in source
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper is a well-conducted observational extension of a randomized trial, with strong reporting of demographics, ethics, resources, and statistical methods. The main weakness is the lack of a power analysis and incomplete specification of inclusion/exclusion criteria for the extension, which limits the strength of causal claims. Minor copyedit issues and an internal inconsistency in the number of reenrolled patients should be corrected.
Both reviewers classified the study as interventional, which was adopted. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal housing, cell lines). The statistics verification recomputed only 4 tests consistently; this is partial coverage and does not validate all reported statistics. The reviewers diverged slightly on reporting guideline (one rated it adequate, the other inadequate), but the overall dimension remains a pass.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.
- CONSISTENTreported p = .120 · recomputed p = .118Reviewer 1Primary effectiveness endpoint comparison (PFA vs thermal) using log-rank test
“The estimated probabilities of 4-year treatment success were 72.8% for PFA and 64.3% for thermal ablation (log-rank P = 0.12; Table ).”
Taken as given: The log-rank test statistic is approximately chi-square with 1 degree of freedom.; The reported p-value is two-sided.Method: Recomputed the p-value from the log-rank chi-square statistic (2.44) using the chi-square distribution with 1 df.How we recomputed it: pChi2(2.44, 1) - CONSISTENTreported p = .040 · recomputed p = .050Reviewers 1, 2Repeat ablation comparison (PFA vs thermal) using Fisher's exact test
“Repeat ablation for AF/AFL/AT | 19 (10.4) | 32 (17.7) | 0.04 | 0.54 (0.29−0.99)”
Taken as given: The numbers 19 and 32 are the event counts in the PFA and thermal groups, respectively.; The group totals are 183 and 181, respectively.; The test used is Fisher's exact test (two-sided).Method: Recomputed the two-sided Fisher's exact test p-value from the 2x2 table.How we recomputed it: pFisher2x2(19, 164, 32, 149, 0) - CONSISTENTreported p = .020 · recomputed p = .022Reviewer 1AAD use comparison (PFA vs thermal) using Fisher's exact test
“On AAD at any time through follow-up | 21 (11.5) | 37 (20.4) | 0.02 | 0.51 (0.28−0.90)”
Taken as given: The numbers 21 and 37 are the event counts in the PFA and thermal groups, respectively.; The group totals are 183 and 181, respectively.; The test used is Fisher's exact test (two-sided).Method: Recomputed the two-sided Fisher's exact test p-value from the 2x2 table.How we recomputed it: pFisher2x2(21, 162, 37, 144, 0) - CONSISTENTreported p = .120 · recomputed p = .121Reviewer 2P-value for primary effectiveness endpoint (treatment success) using log-rank test approximated by chi-square from event counts.
“Treatment success, on-AAD or off-AAD, N events (%) b,c | 134 (72.8) | 119 (64.3) | 0.12”
Taken as given: The numbers 49 and 62 are the failure counts for PFA and thermal groups, respectively.; The group totals are 183 for PFA and 181 for thermal, so successes are 134 and 119, respectively.; The log-rank test p-value is approximated by a chi-square test on the 2x2 table of failures/successes.Method: Chi-square test on the 2x2 table (49, 134, 62, 119) as an approximation to the log-rank test.How we recomputed it: pChi2x2(49, 134, 62, 119)
- lowinternal contradictionThe Discussion states that 323 of 607 patients reenrolled, but the Results state 364 of 607. This discrepancy may be due to different definitions (e.g., those who completed follow-up vs. those who consented), but it is not explained.
“over half of the initial patient cohort enrolled in ADVENT consented to reenroll in ADVENT-LTO (323 of 607 patients)”
Discussion ¶1Find in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions overstated beyond the evidenceAssessed
5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
- overstatedReviewers 1, 2These long-term data support widespread adoption of PFA for the treatment of AF.The study shows non-inferiority and some trends, but the claim of 'widespread adoption' goes beyond the evidence, which is from a single extension study with potential selection bias.Evidence: The study provides 4-year outcomes but does not directly address adoption or comparative effectiveness in broader populations.
“Coupled with the safety advantages of PFA over thermal ablation, these long-term data support widespread adoption of PFA for the treatment of AF.”
AbstractFind in source - supportedReviewers 1, 2PFA demonstrated preserved effectiveness compared to thermal ablation at 4 years.The primary endpoint showed no statistically significant difference (P=0.12), which is consistent with preserved effectiveness (non-inferiority).Evidence: Primary effectiveness endpoint: 72.8% PFA vs 64.3% thermal, P=0.12.
“For the primary endpoint of 4-year treatment success, PFA demonstrated preserved effectiveness compared to thermal ablation (72.8% PFA, 64.3% thermal; P = 0.12).”
AbstractFind in source - supportedReviewers 1, 2There was a trend favoring PFA for freedom from hospital-based arrhythmia intervention.The hazard ratio of 0.64 with 95% CI 0.38-1.05 indicates a trend but not statistical significance, as stated.Evidence: Freedom from hospital-based arrhythmia intervention: 85.6% PFA vs 78.6% thermal, HR=0.64, 95% CI 0.38-1.05.
“there was a trend favoring PFA as compared to thermal ablation for the prespecified outcome of freedom from hospital-based arrhythmia intervention (85.6% PFA, 78.6% thermal; hazard ratio (HR) = 0.64, 95% confidence interval (CI): 0.38−1.05)”
AbstractFind in source - supportedReviewers 1, 2PFA resulted in fewer repeat ablations compared to thermal ablation.The difference was statistically significant (P=0.04), supporting the claim.Evidence: Repeat ablation: 10.4% PFA vs 17.7% thermal, P=0.04.
“including fewer repeat ablations (10.4% PFA, 17.7% thermal; P = 0.04)”
AbstractFind in source - supportedReviewers 1, 2The favorable outcomes of PFA are maintained over 4 years.The primary endpoint and other outcomes show no significant decline over time, and the landmark analysis supports long-term durability.Evidence: Kaplan-Meier curves show a plateau after early failures; landmark analysis shows only 9% recurrence after 1 year.
“Taken together, these data demonstrate that the favorable outcomes of PFA are maintained over the course of 4 years.”
AbstractFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary efficacy endpoint is freedom from atrial tachyarrhythmia recurrence (AF/AT/AFL lasting ≥30 seconds), cardioversion, or repeat ablation. This is a surrogate for clinical outcomes such as stroke or mortality. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD) nor cite validated evidence linking this surrogate to hard clinical outcomes. The claim of 'preserved effectiveness' and 'support widespread adoption' is based on this surrogate.
“For the primary endpoint of 4-year treatment success, PFA demonstrated preserved effectiveness compared to thermal ablation (72.8% PFA, 64.3% thermal; P = 0.12).”
- INADEQUATEEffect sizeThe primary effect size is a 72.8% vs 64.3% success rate, which is not statistically significant (P=0.12). The difference of 8.5 percentage points is not anchored to a minimal clinically important difference or biological meaningfulness. The paper reports trends and non-significant differences, and the only significant finding (fewer repeat ablations) is a secondary endpoint. The effect size is not presented as clinically material.
“the estimated probabilities of 4-year treatment success were 72.8% for PFA and 64.3% for thermal ablation (log-rank P = 0.12)”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Study-design details incomplete (controls, blinding, power)Assessed
The introduction cites multiple randomized trials and large observational studies, acknowledges both strengths and limitations of prior work, and logically motivates the need for long-term follow-up. The rationale for the study is clearly linked to the objective of assessing 4-year outcomes, and limitations of prior studies (e.g., 1-year follow-up) are explicitly addressed.
“Preclinical and early clinical studies demonstrated the safety of PFA on pulmonary vein tissue, phrenic nerves and the esophagus – . Most notably, the clinical safety of PFA has been established in large-scale, center-reported studies of the pentaspline PFA catheter—including the European-centric MANIFEST-17K study of 17,642 patients and the US-centric MANIFEST-US study of 41,698 patients—together demonstrating no pulmonary vein stenosis, permanent phrenic nerve injury or atrio-esophageal fistula , .”
“However, these studies all had a 1-year follow-up, and little is known about the long-term efficacy of PFA in controlling AF.”
“To address these long-term concerns of PFA, we performed extended follow-up to ADVENT .”
“Most notably, the clinical safety of PFA has been established in large-scale, center-reported studies of the pentaspline PFA catheter—including the European-centric MANIFEST-17K study of 17,642 patients and the US-centric MANIFEST-US study of 41,698 patients”
“However, these studies all had a 1-year follow-up, and little is known about the long-term efficacy of PFA in controlling AF.”
Randomization method and unit were from the parent ADVENT trial (1:1, center-level restriction), and blinding of patients was described. However, the extension is observational, with no power analysis for the extension, and inclusion/exclusion criteria are not fully pre-specified for the extension (only completion of 1-year follow-up). Outlier handling is not explicitly addressed, and controls are not applicable as this is a comparative effectiveness study. Independent replication is not applicable for a single extension study.
“Patients were randomly assigned 1:1 to receive either PFA or thermal ablation, with each center limited to using either only RFA or Cryo for all of their control/thermal group patients.”
“Patients were blinded to their treatment assignments during the ADVENT trial.”
“Patients were randomly assigned 1:1 to receive either PFA or thermal ablation”
“Patients were blinded to their treatment assignments during the ADVENT trial.”
The paper reports sex, age, BMI, race/ethnicity, and various comorbidities in Table 1. Since both sexes are enrolled, sex_justified is not applicable. Age, weight (BMI), and health status are reported. Demographics are comprehensive.
“Age (years) | 62.7 ± 8.0 | 62.7 ± 8.2 | 0.98 | 63.1 ± 7.9 | 62.4 ± 8.4 |”
“Sex (female, N (%)) | 60 (32.8) | 67 (37.0)”
“Age (years) | 62.7 ± 8.0 | 62.7 ± 8.2”
The methods state that the study was approved by each center's institutional review board and conducted in accordance with the Declaration of Helsinki. Informed consent is described for both the parent trial and the extension, including consent via legally authorized representatives for deceased patients. Regulatory compliance is explicitly stated.
“The study was approved by each center’s institutional review board and conducted in accordance with the Declaration of Helsinki.”
“The cohort of patients eligible for these analyses were contacted by their respective sites at least 3 years after the index procedure to consider study enrollment and provide written informed consent for ADVENT-LTO participation.”
“The study was approved by each center’s institutional review board and conducted in accordance with the Declaration of Helsinki.”
“The cohort of patients eligible for these analyses were contacted by their respective sites at least 3 years after the index procedure to consider study enrollment and provide written informed consent for ADVENT-LTO participation.”
The PFA catheter (Farawave; Boston Scientific) and cryoballoon (Arctic Front Advance; Medtronic) are identified. The Holter analysis software (Preventice Solutions, Inc.) is named. No antibodies, cell lines, or other biological reagents are used, so those criteria are not applicable.
“For PFA, the pentaspline PFA catheter (Farawave; Boston Scientific) was delivered over the wire to each pulmonary vein, and pulsed field energy was delivered to achieve electrical isolation.”
“For arrhythmia detection, 7-day Holter monitoring was performed, and the data were analyzed by a core laboratory using an artificial intelligence-based cardiac algorithm (Preventice Solutions, Inc.).”
“For PFA, the pentaspline PFA catheter (Farawave; Boston Scientific) was delivered over the wire to each pulmonary vein”
“for Cryo, the balloon catheter (Arctic Front Advance; Medtronic) was advanced to each vein for ablation.”
“Analyses were performed using SAS version 9.4 software (SAS Institute).”
The paper names the statistical tests used (log-rank, Fisher's exact, chi-square, ANOVA, Kruskal-Wallis, Cox regression). Effect sizes (HRs, ORs) with 95% CIs are reported for key endpoints. Exact p-values are provided for many comparisons. The paper explicitly states that all analyses are exploratory and nominal p-values should not be interpreted as inferential. Data presentation includes Kaplan-Meier curves and per-group n. Mathematical plausibility checks were not performed due to the nature of the data (continuous outcomes, large N).
“Comparisons of chronic success between treatment groups (ablation modalities) were performed using the log-rank test. Additional time-to-event endpoints were summarized using HRs and 95% CIs. Binary outcomes were summarized as proportions with odds ratios and 95% CIs, and group comparisons were conducted using Fisher’s exact test or chi-square test, as appropriate.”
“Treatment success, on-AAD or off-AAD, N events (%) b,c | 134 (72.8) | 119 (64.3) | 0.12 | 0.75 (0.52−1.09)”
“Analyses were performed using SAS version 9.4 software (SAS Institute).”
“Comparisons of chronic success between treatment groups (ablation modalities) were performed using the log-rank test.”
“HR = 0.64, 95% CI: 0.38−1.05”
The data availability statement provides a specific mechanism: qualified researchers may request access through the Boston Scientific data sharing portal, with an Independent Scientific Review Committee evaluating requests monthly. This is a concrete managed-access route, so it is adequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.
“Qualified researchers may request access through the Boston Scientific data sharing portal ( https://www.bostonscientific.com/en-US/data-sharing-requests/data-sharing-request-submission-form.html ) under a data use agreement and appropriate confidentiality safeguards. Requests are evaluated monthly by an Independent Scientific Review Committee, with decisions issued within 2 months.”
“Qualified researchers may request access through the Boston Scientific data sharing portal ( https://www.bostonscientific.com/en-US/data-sharing-requests/data-sharing-request-submission-form.html ) under a data use agreement and appropriate confidentiality safeguards. Requests are evaluated monthly by an Independent Scientific Review Committee, with decisions issued within 2 months.”
Methods are detailed enough for replication. The study is registered (NCT06526546). Limitations are explicitly discussed, including the observational nature, potential selection bias, and incomplete Holter monitoring. Conclusions are appropriately cautious, noting trends and exploratory analyses. Funding and competing interests are disclosed.
“ClinicalTrials.gov registration: NCT06526546 (https://clinicaltrials.gov/study/NCT06526546) .”
“This study has limitations. First, this study was observational and retrospectively enrolled 364 of the 607 patients in the ADVENT cohort, and the reenrolled thermal ablation group did show a non-significant bias toward failure compared to non-enrolled ADVENT patients.”
“This study was funded by Boston Scientific, Inc.”
“ClinicalTrials.gov registration: NCT06526546”
“This study has limitations. First, this study was observational and retrospectively enrolled 364 of the 607 patients in the ADVENT cohort”
“This study was funded by Boston Scientific, Inc.”
Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 43 references by DOI: 43 verified.
Every extracted reference resolved against Crossref/OpenAlex with no retraction flags.
4 data/code links checked; 4 live.
- datahttps://clinicaltrials.gov/study/NCT06526546LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT06526546LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT04612244LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://www.bostonscientific.com/en-US/data-sharing-requests/data-sharing-request-submission-form.htmlLIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
4 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 4 minor suggestions below.
4 copyedit issues flagged: mostly consistency, typo, clarity.
- MINORtypoAbstract“arrythmia”→ arrhythmiaMisspelling of 'arrhythmia' in the abstract.
- MINORconsistencyDiscussion, paragraph 1“323 of 607 patients”→ 364 of 607 patientsThe number of reenrolled patients is stated as 323 in the Discussion but 364 in the Results; should be consistent.
- MINORclarityMethods, Statistical analysis“All analyses are exploratory and hypothesis generating.”→ All analyses are exploratory and hypothesis-generating.Add hyphen for clarity.
- MINORconsistencyResults, Hospital-based arrythmia intervention and AF progression“The median time to repeat ablation was 350 days (IQR: 132−777) for thermal ablation and 434 days (IQR: 157−822) for PFA”→ The median time to repeat ablation was 350 days (IQR: 132−777) for PFA and 434 days (IQR: 157−822) for thermal ablationThe order of groups is reversed compared to Table 2, which lists PFA first.
The published work is robust in its reporting and transparency, but readers should weigh the observational nature of the extension, the lack of a power analysis, and the potential selection bias from reenrollment. The internal inconsistency in the number of reenrolled patients (323 vs 364) and the overstated claim of 'widespread adoption' warrant attention; an erratum or clarification may be appropriate.
- 1.HIGHreportingReconcile the number of reenrolled patients in the Discussion (323) with the Results (364) and explain the discrepancy or correct the error.An internal contradiction in a key number undermines the paper's credibility and could be flagged by readers or reviewers.
- 2.HIGHrigorAdd a power analysis or sample size justification for the ADVENT-LTO extension in the Methods section, even if post hoc.The absence of a power analysis for the extension weakens the statistical foundation and is a common reviewer concern.
- 3.HIGHrigorProvide a detailed summary of the inclusion and exclusion criteria for ADVENT-LTO in the Methods, rather than only referencing the parent trial protocol.Incomplete specification of eligibility criteria for the extension limits reproducibility and transparency.
- 4.HIGHreportingTemper the claim 'These long-term data support widespread adoption of PFA for the treatment of AF' to reflect the study's limitations, such as the observational extension and potential selection bias.The claim overstates the evidence from a single extension study with non-inferiority results and a non-significant bias toward failure in the thermal group.
- 5.MEDIUMstatisticsExplicitly state how missing data (e.g., from patients who did not undergo Holter monitoring) were handled in the statistical analysis.Clarifying missing data handling strengthens the statistical analysis and addresses a reviewer suggestion.
- 6.MEDIUMstatisticsAdd a brief statement on verification of statistical assumptions (e.g., proportional hazards for Cox models) in the Methods.Reporting assumption checks improves the rigor of the statistical analysis.
- 7.MEDIUMreportingExplicitly state adherence to a reporting guideline such as STROBE for observational studies in the Reporting Summary.One reviewer noted the reporting guideline was not explicitly named; stating it improves transparency.
- 8.MEDIUMcopyeditFix the typo 'arrythmia' to 'arrhythmia' in the Abstract.Correcting the misspelling improves professionalism and readability.
- 9.MEDIUMcopyeditCorrect the order of groups in the sentence about median time to repeat ablation in the Results to match Table 2 (PFA first).Consistency in group ordering prevents confusion and aligns with the table presentation.
- 10.LOWcopyeditAdd a hyphen in 'hypothesis generating' to 'hypothesis-generating' in the Methods.Minor grammatical improvement for clarity.
- 11.LOWreportingConsider reporting the number of patients with missing data for each endpoint and how missing data were handled.Transparency about missing data enhances the completeness of reporting.
- 12.LOWreportingClarify the role of the sponsor in data analysis and the independence of the analysis in the Methods.Sponsor involvement is a common concern; clarifying independence strengthens trust.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.